A secondary analysis of the FINEARTS-HF study has revealed that finerenone, a nonsteroidal mineralocorticoid receptor antagonist (nsMRA), could prevent outpatient worsening heart failure (HF) events requiring oral diuretic intensification in individuals with mildly reduced or preserved ejection fraction. This study, which involved approximately 6,000 participants, found that finerenone reduced oral diuretic intensification rates by 11%.

Heart failure is a significant health issue in the United States, with millions of Americans affected. According to the Centers for Disease Control and Prevention (CDC), about 6.2 million adults in the U.S. have heart failure. The condition is a leading cause of hospitalization and contributes to significant healthcare costs. The findings from the FINEARTS-HF study offer new hope for managing this chronic condition more effectively.

The study, led by researchers from Brigham and Women’s Hospital, highlights the importance of outpatient oral diuretic intensification as an early marker of worsening heart failure. The team noted that “These results support the use of outpatient oral diuretic intensification as an early marker of worsening HF and indicate that the benefit of finerenone in decreasing worsening HF events in patients with HF with mildly reduced or preserved ejection fraction extends to the outpatient setting.”

Oral diuretic initiation or intensification has been linked to a 2.5 to 3-fold higher risk of subsequent mortality compared with stable outpatients. These elevated risks are similar to outpatient intravenous diuretic administration, although lower than HF hospitalization. The study underscores the need for early intervention and monitoring to prevent adverse outcomes in heart failure patients.

A global, multi-center, randomized clinical trial, FINEARTS-HF compared finerenone with a placebo among a population with HF with mildly reduced or preserved ejection fraction on a loop or thiazide diuretic at baseline. After analysis, finerenone lowered total worsening HF events and cardiovascular death by 16%. Outpatient oral diuretic intensification, defined as a change in the dosage of loop diuretics or the initiation of thiazide diuretics, served as a prespecified exploratory outcome.

The trial enrolled 6,001 participants, with a mean age of 72.0 years, and 2,732 (46%) female. Upon analysis, the researchers identified the first worsening HF events as comprised of 664 (11%) HF hospitalizations, 87 (1%) urgent HF visits, and 1,250 (21%) oral diuretic intensifications.

Mortality rates were increased after worsening HF events, including hospitalization (27.7 per 100 patient-years; 95% CI, 24.3–31.5), urgent HF visits (13.6 per 100 patient-years; 95% CI, 8.8–21.1), and outpatient oral diuretic intensification (11.6 per 100 patient-years; 95% CI, 10.2–13.1). By comparison, patients without worsening HF events experienced lower mortality (4.5 events per 100 patient-years; 95% CI, 4.2–4.9).

Further analysis showed 756 outpatient oral diuretic intensification events in the finerenone group, compared with 832 in the placebo group. Finerenone demonstrated a reduction in the first outpatient oral diuretic intensification by 11% (hazard ratio [HR] 0.89 [95% CI, 0.80–0.98]; P = .02).

The addition of outpatient oral diuretic intensification heightened the number of patients reporting events, with an increase from 1,343 to 2,238. In an extended composite outcome of cardiovascular death, HF hospitalization, and urgent HF visit, finerenone reduced the risk by 15% (HR, 0.85 [95% CI, 0.78–0.92]; P <.001).

The researchers noted that oral diuretic intensification demonstrated a nearly 2-fold increase in subsequent mortality, compared with stable outpatients, a similar rate to centrally adjudicated urgent HF visits requiring intravenous (IV) therapy. In this FINEARTS-HF analysis, finerenone decreased the risk of oral diuretic intensification alone and as part of an extended composite outcome.

“We now show that finerenone also reduced the clinically meaningful outcome of outpatient oral diuretic intensification by 11% and an extended composite including the primary outcome by 15%,” the researchers added. “These results indicate that the benefits of finerenone extend to reductions in outpatient worsening HF.”

The implications of these findings are substantial. Finerenone’s ability to reduce outpatient worsening HF events could lead to fewer hospitalizations and improved quality of life for patients. This is particularly relevant in the U.S., where heart failure is a major public health concern. The study’s results suggest that early intervention with finerenone could be a crucial strategy in managing heart failure more effectively.

However, it is important to note that while finerenone shows promise, it is not a cure-all. Patients and healthcare providers must continue to monitor and manage heart failure through a combination of medications, lifestyle changes, and regular check-ups. The study’s findings should be integrated into broader treatment plans that consider each patient’s unique needs and circumstances.

In conclusion, the FINEARTS-HF study provides compelling evidence that finerenone can significantly reduce outpatient worsening HF events. This breakthrough offers new hope for the millions of Americans living with heart failure and underscores the importance of early intervention and continuous monitoring in managing this chronic condition.